This individual participant data meta-analysis found no evidence that combined oral contraceptives or norethisterone enanthate use increases women’s risk of HIV, but the analysis adds to the evidence that depot-medroxyprogesterone acetate (DMPA) may increase HIV risk. The finding underscores the need for additional safe and effective contraceptive options for women at high risk for HIV. A randomized controlled trial would provide more definitive evidence about the effects of hormonal contraception, particularly DMPA, on HIV risk.
Hormonal contraception and the risk of HIV acquisition: An individual participant data meta-analysis
Written By
Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N.
